abrdn plc Takes $12.20 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)

abrdn plc acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 194,232 shares of the company’s stock, valued at approximately $12,198,000. abrdn plc owned about 0.20% of Vaxcyte as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PCVX. Westfield Capital Management Co. LP acquired a new stake in shares of Vaxcyte in the third quarter valued at approximately $51,180,000. Eventide Asset Management LLC acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $20,035,000. Jennison Associates LLC lifted its holdings in Vaxcyte by 20.6% during the 3rd quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after purchasing an additional 300,189 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Vaxcyte by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after purchasing an additional 167,501 shares during the last quarter. Finally, Moody Aldrich Partners LLC lifted its holdings in Vaxcyte by 468.3% during the 3rd quarter. Moody Aldrich Partners LLC now owns 140,170 shares of the company’s stock worth $7,146,000 after purchasing an additional 115,505 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on PCVX shares. Needham & Company LLC reissued a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a report on Wednesday, April 10th. Bank of America lifted their price target on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $78.50.

Insider Activity

In other news, CEO Grant Pickering sold 30,000 shares of Vaxcyte stock in a transaction on Monday, January 29th. The stock was sold at an average price of $66.03, for a total value of $1,980,900.00. Following the transaction, the chief executive officer now owns 375,814 shares in the company, valued at approximately $24,814,998.42. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Monday, March 18th. The stock was sold at an average price of $69.02, for a total value of $552,160.00. Following the transaction, the chief financial officer now owns 95,679 shares in the company, valued at approximately $6,603,764.58. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 30,000 shares of Vaxcyte stock in a transaction on Monday, January 29th. The shares were sold at an average price of $66.03, for a total value of $1,980,900.00. Following the completion of the transaction, the chief executive officer now owns 375,814 shares in the company, valued at approximately $24,814,998.42. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,577 shares of company stock worth $7,400,635. Insiders own 3.60% of the company’s stock.

Vaxcyte Stock Down 0.4 %

Shares of NASDAQ PCVX opened at $60.06 on Friday. The business has a fifty day moving average price of $68.25 and a two-hundred day moving average price of $61.27. Vaxcyte, Inc. has a fifty-two week low of $41.57 and a fifty-two week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the previous year, the business earned ($0.73) earnings per share. As a group, equities analysts anticipate that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.